COVID-Out double-blind randomized trial tested #metformin, ivermectin, or fluvoxamine for outpatient #COVID19. Secondary endpoint was incidence of Long Covid (PASC). Volunteers were followed monthly to 10 mo. Metformin 42% reduction in Long Covid.https://t.co/eqJR4aqj8U — David Boulware, MD MPH (@boulware_dr) December 25, 2022
COVID-Out double-blind randomized trial tested #metformin, ivermectin, or fluvoxamine for outpatient #COVID19. Secondary endpoint was incidence of Long Covid (PASC). Volunteers were followed monthly to 10 mo. Metformin 42% reduction in Long Covid.https://t.co/eqJR4aqj8U — David Boulware, MD MPH (@boulware_dr) December 25, 2022
COVID-Out double-blind randomized trial tested #metformin, ivermectin, or fluvoxamine for outpatient #COVID19. Secondary endpoint was incidence of Long Covid (PASC). Volunteers were followed monthly to 10 mo. Metformin 42% reduction in Long Covid.https://t.co/eqJR4aqj8U — David Boulware, MD MPH (@boulware_dr) December 25, 2022
神药
primary failed了,secondary数据看起来也不多不怕multiple testing的问题么